138 reports of this reaction
2.5% of all CARVEDILOL PHOSPHATE reports
#7 most reported adverse reaction
BLOOD PRESSURE INCREASED is the #7 most commonly reported adverse reaction for CARVEDILOL PHOSPHATE, manufactured by Waylis Therapeutics LLC. There are 138 FDA adverse event reports linking CARVEDILOL PHOSPHATE to BLOOD PRESSURE INCREASED. This represents approximately 2.5% of all 5,587 adverse event reports for this drug.
Patients taking CARVEDILOL PHOSPHATE who experience blood pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD PRESSURE INCREASED is a less commonly reported adverse event for CARVEDILOL PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to blood pressure increased, the following adverse reactions have been reported for CARVEDILOL PHOSPHATE:
The following drugs have also been linked to blood pressure increased in FDA adverse event reports:
BLOOD PRESSURE INCREASED has been reported as an adverse event in 138 FDA reports for CARVEDILOL PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD PRESSURE INCREASED accounts for approximately 2.5% of all adverse event reports for CARVEDILOL PHOSPHATE, making it a notable side effect.
If you experience blood pressure increased while taking CARVEDILOL PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.